Abstract
Background: Diabetic foot syndrome (DFS), particularly in its ischemic and neuroischemic forms, is a major cause of amputation and mortality in patients with type 2 diabetes mellitus. When combined with coronary artery disease (CAD), the risks of poor outcomes increase substantially. Endovascular revascularization has emerged as a preferred approach for limb salvage, yet clinical results vary depending on cardiovascular status and timing of intervention.
Methods: This review summarizes the current literature on endovascular management of diabetic foot complications in patients with coexisting CAD. It focuses on treatment sequencing, procedural access, revascularization efficacy, and patient selection. Clinical challenges and future directions for personalized intervention algorithms are also discussed.
Results: Patients with advanced DFS and concomitant CAD often require careful risk stratification before revascularization. Factors such as ejection fraction, anatomical accessibility, ulcer staging, and coronary reserve influence outcomes. Studies support the efficacy of limb-first or heart-first strategies depending on individual risk profiles. Preprocedural planning and coordinated care are essential to reduce amputation rates, repeat interventions, and perioperative complications.
Conclusion: Endovascular treatment offers promising outcomes for patients with diabetic foot complications and CAD when applied within a structured, risk-oriented framework. Personalized decision-making, based on cardiac status and ischemic severity, should guide therapeutic priorities to maximize limb preservation and survival.
References
Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376(24):2367–75.
Mills JL, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery lower extremity threatened limb classification system. J Vasc Surg. 2014;59(1):220–34.
Hinchliffe RJ, Brownrigg JR, Andros G, et al. Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease. Diabetes Metab Res Rev. 2016;32(S1):136–44.
Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(S1):S1–75.
Harskamp RE, Lopes RD, Baisden CE, de Winter RJ, Alexander JH. Synchronized management of coronary and peripheral artery disease. J Am Coll Cardiol. 2014;63(7):635–43.
Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6S):3S–125S.e40.
Spiliopoulos S, Pastromas G, Kitrou P, et al. Outcomes of staged versus simultaneous coronary and peripheral interventions in diabetic patients with limb ischemia. Cardiovasc Intervent Radiol. 2017;40(5):713–21.
Bunte MC, Jacob S, Reinecke H, et al. Diabetic foot and coronary artery disease: the need for coordinated revascularization strategies. Eur Heart J Suppl. 2020;22(Suppl E):E95–E101.
Zhan LX, Branco BC, Armstrong EJ, et al. Outcomes of percutaneous interventions for critical limb ischemia in patients with and without diabetes. J Vasc Surg. 2015;62(5):1187–95.
Sumpio BE. Contemporary diagnosis and management of the diabetic foot. In: Cameron JL, ed. Current Surgical Therapy. 12th ed. Philadelphia: Elsevier; 2017:888–92.
Choi ET. Current status of endovascular treatment for lower extremity peripheral arterial disease. Vasc Health Risk Manag. 2009;5:749–59.
Soderstrom M, Arvela E, Lepantalo M. The impact of a multidisciplinary team approach on diabetic foot care. Eur J Vasc Endovasc Surg. 2010;40(3):360–5.
Okamoto S, Shiraki T, Haraguchi M, et al. Predictive value of cardiac function in healing of diabetic foot ulcers after revascularization. Circ J. 2013;77(2):441–6.
Wang J, Wu H, Zheng Z, et al. Clinical outcomes of endovascular treatment in patients with diabetic foot disease and concomitant coronary artery disease. J Diabetes Complications. 2021;35(6):107963.
Tan T, Shaw EJ, Siddiqui F, et al. Inpatient management of diabetic foot problems: a clinical guideline from the National Institute for Health and Clinical Excellence (NICE). Diabet Med. 2019;36(6):730–8.